Janani Saikumar1, Krithika Ramachandran1, Vishal S Vaidya2. 1. Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and Department of Environmental Health, Harvard School of Public Health, Boston, MA. 2. Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and Department of Environmental Health, Harvard School of Public Health, Boston, MA. vvaidya@partners.org.
Abstract
BACKGROUND: The recent revolutionary advances made in genome-wide sequencing technology have transformed biology and molecular diagnostics, allowing new sRNA (small RNA) classes to be discovered as potential disease-specific biological indicators. Cell-free microRNAs (miRNAs) have been shown to exist stably in a wide spectrum of body fluids and their expression profiles have been shown to reflect an assortment of physiological conditions, underscoring the utility of this new class of molecules to function as noninvasive biomarkers of disease. CONTENT: We summarize information on the known mechanisms of miRNA protection and release into extracellular space and compile the current literature on extracellular miRNAs that have been investigated as biomarkers of 20 different cancers, 11 organ damage conditions and 10 diverse disease states. We also discuss the various strategies involved in the miRNA biomarker discovery workflow and provide a critical opinion on the impediments faced by this advancing field that need to be overcome in the laboratory. SUMMARY: The field of miRNA-centered diagnostics is still in its infancy, and basic questions with regard to the exact role of miRNAs in the pathophysiology of diseases, and the mechanisms of their release from affected cells into biological fluids are yet to be completely understood. Nevertheless, these noninvasive micromarkers have immense potential in translational medicine not only for use in monitoring the efficacy and safety of therapeutic regimens but also to guide the diagnosis of diseases, to determine the risk of developing diseases or conditions, and more importantly, to inform treatment options.
BACKGROUND: The recent revolutionary advances made in genome-wide sequencing technology have transformed biology and molecular diagnostics, allowing new sRNA (small RNA) classes to be discovered as potential disease-specific biological indicators. Cell-free microRNAs (miRNAs) have been shown to exist stably in a wide spectrum of body fluids and their expression profiles have been shown to reflect an assortment of physiological conditions, underscoring the utility of this new class of molecules to function as noninvasive biomarkers of disease. CONTENT: We summarize information on the known mechanisms of miRNA protection and release into extracellular space and compile the current literature on extracellular miRNAs that have been investigated as biomarkers of 20 different cancers, 11 organ damage conditions and 10 diverse disease states. We also discuss the various strategies involved in the miRNA biomarker discovery workflow and provide a critical opinion on the impediments faced by this advancing field that need to be overcome in the laboratory. SUMMARY: The field of miRNA-centered diagnostics is still in its infancy, and basic questions with regard to the exact role of miRNAs in the pathophysiology of diseases, and the mechanisms of their release from affected cells into biological fluids are yet to be completely understood. Nevertheless, these noninvasive micromarkers have immense potential in translational medicine not only for use in monitoring the efficacy and safety of therapeutic regimens but also to guide the diagnosis of diseases, to determine the risk of developing diseases or conditions, and more importantly, to inform treatment options.
Authors: Patricia Puerta-Gil; Rodrigo García-Baquero; Angela Y Jia; Sara Ocaña; Miguel Alvarez-Múgica; Jose L Alvarez-Ossorio; Carlos Cordon-Cardo; Fernando Cava; Marta Sánchez-Carbayo Journal: Am J Pathol Date: 2012-03-15 Impact factor: 4.307
Authors: Pablo Menéndez; Pedro Villarejo; David Padilla; José M Menéndez; Jose A Rodríguez Montes Journal: J Surg Oncol Date: 2012-08-17 Impact factor: 3.454
Authors: Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley Journal: Nat Cell Biol Date: 2011-03-20 Impact factor: 28.824
Authors: S Miah; E Dudziec; R M Drayton; A R Zlotta; S L Morgan; D J Rosario; F C Hamdy; J W F Catto Journal: Br J Cancer Date: 2012-05-29 Impact factor: 7.640
Authors: Mariana Cardenas-Gonzalez; Anand Srivastava; Mira Pavkovic; Vanesa Bijol; Helmut G Rennke; Isaac E Stillman; Xiaolan Zhang; Samir Parikh; Brad H Rovin; Maryam Afkarian; Ian H de Boer; Jonathan Himmelfarb; Sushrut S Waikar; Vishal S Vaidya Journal: Clin Chem Date: 2017-06-30 Impact factor: 8.327